BNC KOREA. Inc.
KKRX:2568402,560.00
KRW
-105.00
(-3.94%)
ISIN
KR7256840000
Return %
Stock
S&P 500
1Y
-47.70
14.39
3Y
-16.75
81.42
5Y
-90.33
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Wan-Kyu Choi
- Full Time Employees
- 295
- Sector
- Retail trade
- Industry
- Specialty stores
- Address
- #405, Structure 1 Daegu DA South Korea
- IPO Date
- Dec 28, 2016
- Website
- bnckorea.co.kr
- Similar Companies
- Business
- BNC Korea Co., Ltd. is a South Korean biotechnology company primarily engaged in the research, development, manufacture, and sale of biopharmaceuticals, medical devices, and aesthetic medical products. Founded in 2007 and headquartered in Seongnam, South Korea, the company’s core product portfolio includes hyaluronic acid (HA) dermal fillers under brands such as Cutegel, Cutegel Lidocaine, and FLORE Lidocaine; biological products including antibiotics and medicinal chemicals; collagen wound dressings; anti-adhesion barrier materials; wound healing materials; skin booster fillers; lifting threads; fat dissolvers like DR.LIPO+; and additional pharmaceutical and cosmetic products. BNC Korea supplies these products across global markets, with distribution extending to over 35 countries, including regions in Russia, the Middle East, Europe, India, Brazil, and China. In recent years, BNC Korea has strategically transitioned from being chiefly a distributor to becoming a fully capable manufacturer with a focus on pharmaceutical-grade aesthetic medical devices. This transformation included the acquisition and conversion of a semiconductor plant into a state-of-the-art manufacturing and R&D facility adhering to pharmaceutical-grade standards, which are more stringent than medical device grade. The company has continued to expand its product innovation and pipeline, introducing advanced aesthetic products like the HANHEAL Exosome Facial Rejuvenation and HYALACE exosome boosters and has showcased around 26 brands in international exhibitions such as Dubai Derma 2024. Major recent corporate developments include a strategic partnership and research alliance with WizMedi Bio in 2023 focusing on the development of new botulinum toxin products and a 2022 acquisition of a 63.2% stake in Dong-in Biotech Co., Ltd., to enhance its biopharmaceutical capabilities. Additionally, BNC Korea collaborates on research and commercialization projects, such as a GLP1-agonist against diabetes and obesity in partnership with SML Biopharm. In 2025, BNC Korea obtained approval from the China National Medical Products Administration (NMPA) for several products, further consolidating its international market presence. BNC Korea operates within the pharmaceuticals and biotechnology sectors, targeting healthcare providers, medical aesthetics specialists, and global distributors. The company employs advanced manufacturing technologies and maintains a clean room system alongside sophisticated production lines for high-viscosity prefilled syringes and lyophilized products. These efforts underscore BNC Korea’s commitment to expanding its footprint in the biopharmaceutical and medical aesthetics industries while advancing cutting-edge product development and global market penetration.